Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.
Ricaurte
G A
GA
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Finnegan
K T
KT
Irwin
I
I
Langston
J W
JW
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D001679:Biogenic Amines / Q000134:cerebrospinal fluid*; D015198:Designer Drugs / Q000494:pharmacology*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D012016:Reference Values; D019966:Substance-Related Disorders
D001679:Biogenic Amines; D015198:Designer Drugs; D015104:3,4-Methylenedioxyamphetamine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D006719:Homovanillic Acid